Literature DB >> 29147913

Expression of TLR7, TLR9, JAK2, and STAT3 genes in peripheral blood mononuclear cells from patients with systemic sclerosis.

Miša Vreća1, Ana Zeković2, Nemanja Damjanov2,3, Marina Andjelković1, Milena Ugrin1, Sonja Pavlović1, Vesna Spasovski4.   

Abstract

Systemic sclerosis (SSc) is a rare, chronic, multisystem autoimmune disease clinically characterized by progressive fibrosis of the skin and internal organs. The basic mechanism appears to involve endothelial cell injury, overproduction of extracellular matrix proteins, and aberrant immune activation. So far, there have been a few attempts to find genetic biomarkers for monitoring disease activity or for correlation with certain symptoms. In order to reveal reliable biomarkers, we analyzed the expression of four genes representing three important signaling pathways, TLR7, TLR9, and JAK2-STAT3. Using RT-qPCR technique, we analyzed the expression of TLR7, TLR9, JAK2, and STAT3 genes in peripheral blood mononuclear cells of 50 SSc patients and 13 healthy individuals. We detected significant upregulation of TLR7 gene expression in a group of SSc patients compared to non-SSc group. Receiver operating characteristic (ROC) analysis showed that TLR7 expression efficiently discriminates SSc cases from healthy individuals. High TLR7 expression positively correlated with the late form of disease, active SSc, and the presence of digital ulcers. Decreased levels of TLR9 and JAK2 mRNA were found in the patient's cohort in comparison to non-SSc individuals, but showed no correlation with specific clinical outcomes. The expression level of the STAT3 gene did not differ between the analyzed groups. This is the first study on the expression of TLR7, TLR9, and STAT3 genes in SSc patients. Our results show that TLR7, TLR9, and JAK2 genes are potential biomarkers for SSc. The results obtained in this study could contribute to better classification, monitoring, and outcome prediction of patients with SSc based on genetics.

Entities:  

Keywords:  Gene expression; Genetic biomarkers; Systemic sclerosis

Mesh:

Substances:

Year:  2017        PMID: 29147913     DOI: 10.1007/s13353-017-0415-4

Source DB:  PubMed          Journal:  J Appl Genet        ISSN: 1234-1983            Impact factor:   3.240


  50 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Expression, subcellular localization and cytokinic modulation of Toll-like receptors (TLRs) in normal human keratinocytes: TLR2 up-regulation in psoriatic skin.

Authors:  Edouard Begon; Laurence Michel; Béatrice Flageul; Isabelle Beaudoin; Francette Jean-Louis; Hervé Bachelez; Louis Dubertret; Philippe Musette
Journal:  Eur J Dermatol       Date:  2007-10-19       Impact factor: 3.328

Review 3.  IL-6 signal transduction and its physiological roles: the signal orchestration model.

Authors:  D Kamimura; K Ishihara; T Hirano
Journal:  Rev Physiol Biochem Pharmacol       Date:  2003-04-05       Impact factor: 5.545

Review 4.  Scleroderma: from cell and molecular mechanisms to disease models.

Authors:  David J Abraham; John Varga
Journal:  Trends Immunol       Date:  2005-09-15       Impact factor: 16.687

Review 5.  JAK/STAT signal transduction: regulators and implication in hematological malignancies.

Authors:  Lyne Valentino; Josiane Pierre
Journal:  Biochem Pharmacol       Date:  2006-01-19       Impact factor: 5.858

6.  Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8.

Authors:  Florian Heil; Hiroaki Hemmi; Hubertus Hochrein; Franziska Ampenberger; Carsten Kirschning; Shizuo Akira; Grayson Lipford; Hermann Wagner; Stefan Bauer
Journal:  Science       Date:  2004-02-19       Impact factor: 47.728

7.  TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients.

Authors:  Pingping Wu; Jiang Wu; Shuxun Liu; Xinghai Han; Jianqiang Lu; Yeqing Shi; Jianli Wang; Liwei Lu; Xuetao Cao
Journal:  Clin Immunol       Date:  2008-08-05       Impact factor: 3.969

Review 8.  Role of toll-like receptors in systemic sclerosis.

Authors:  Marzena Ciechomska; Rachel Cant; James Finnigan; Jacob M van Laar; Steven O'Reilly
Journal:  Expert Rev Mol Med       Date:  2013-08-28       Impact factor: 5.600

9.  Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database.

Authors:  Florian M P Meier; Klaus W Frommer; Robert Dinser; Ulrich A Walker; Laszlo Czirjak; Christopher P Denton; Yannick Allanore; Oliver Distler; Gabriela Riemekasten; Gabriele Valentini; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2012-05-21       Impact factor: 19.103

10.  RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement.

Authors:  Christina M Lau; Courtney Broughton; Abigail S Tabor; Shizuo Akira; Richard A Flavell; Mark J Mamula; Sean R Christensen; Mark J Shlomchik; Gregory A Viglianti; Ian R Rifkin; Ann Marshak-Rothstein
Journal:  J Exp Med       Date:  2005-10-31       Impact factor: 14.307

View more
  2 in total

Review 1.  Toll-like receptors in mediating pathogenesis in systemic sclerosis.

Authors:  L Frasca; R Lande
Journal:  Clin Exp Immunol       Date:  2020-02-21       Impact factor: 4.330

2.  Variety of endosomal TLRs and Interferons (IFN-α, IFN-β, IFN-γ) expression profiles in patients with SLE, SSc and MCTD.

Authors:  A Paradowska-Gorycka; A Wajda; B Stypinska; E Walczuk; E Rzeszotarska; M Walczyk; E Haladyj; K Romanowska-Prochnicka; A Felis-Giemza; A Lewandowska; M Olesińska
Journal:  Clin Exp Immunol       Date:  2021-01-17       Impact factor: 5.732

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.